Collegium Pharmaceuticals reported Q2 2026 net product revenue of $199.9M, up 6% YoY. Growth in its ADHD franchise and BELBUCA helped offset lower NUCYNTA pain franchise revenue, supporting a modestly positive top-line print.
Collegium Pharmaceuticals reported Q2 2026 net product revenue of $199.9M, up 6% YoY. Growth in its ADHD franchise and BELBUCA helped offset lower NUCYNTA pain franchise revenue, supporting a modestly positive top-line print.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
